November 14, 2011
Anadys Pharmaceuticals Inc. shareholders on Monday targeted the company's leadership along with Swiss drug giant Roche Holdings Inc. in a proposed class action accusing the two drugmakers of undervaluing Anadys stock in its planned $230 million sale to Roche.